Article
Biochemistry & Molecular Biology
Jiadi Lv, Yaoping Liu, Feiran Cheng, Jiping Li, Yabo Zhou, Tianzhen Zhang, Nannan Zhou, Cong Li, Zhenfeng Wang, Longfei Ma, Mengyu Liu, Qiang Zhu, Xiaohan Liu, Ke Tang, Jingwei Ma, Huafeng Zhang, Jing Xie, Yi Fang, Haizeng Zhang, Ning Wang, Yuying Liu, Bo Huang
Summary: Microfluidic devices can sort cancer stem cells into mechanically stiff and soft subpopulations, with soft tumor cells showing higher tumorigenicity. The upregulation of Wnt signaling protein BCL9L in soft tumor cells is associated with their stemness and tumorigenicity. These findings suggest that intrinsic softness can serve as a unique marker for highly tumorigenic and metastatic tumor cells.
Article
Medicine, Research & Experimental
Wenjie Yang, Ke Wang, Jianbin Ma, Ke Hui, Wei Lv, Zhenkun Ma, Mengxi Huan, Lin Luo, Xinyang Wang, Lei Li, Yule Chen
Summary: Recent studies suggest that ADT may accelerate PCa metastasis by regulating the expression of ANXA1 and the migration of PCa cells. The expression of ANXA1 was found to be inversely associated with AR in PCa, and functional assays demonstrated the role of ANXA1 in promoting cell migration. Transcriptome analysis revealed that ANXA1 regulates several genes involved in cell junction organization.
ARCHIVES OF MEDICAL RESEARCH
(2021)
Article
Multidisciplinary Sciences
Agoston G. Nagy, Inna Szekacs, Attila Bonyar, Robert Horvath
Summary: This study successfully observed and quantified the invasiveness of cancer cells using digital holographic microscopy. The invasion speed of cancer cells was found to have a linear relationship with cell migration capability.
SCIENTIFIC REPORTS
(2022)
Article
Cell Biology
Xiaofeng Zhang, Yinshan Bai, Li Huang, Shanshan Liu, Yanxuan Mo, Wei Cheng, Guangliang Wang, Zhiming Cao, Xiaogang Chen, Huiqing Cui, Ling Qi, Lei Ma, Ming Liu, Xin-Yuan Guan, Ning-Fang Ma
Summary: The study reveals a previously unknown function of CHD1L in regulating tumor migration via ZKSCAN3-mediated autophagy in HCC. Inhibiting CHD1L and its downstream autophagy signaling may provide new insights into cancer therapeutics.
CELL DEATH & DISEASE
(2021)
Article
Cell Biology
Attila Varga, Minh Tu Nguyen, Kinga Penzes, Bence Batai, Pal Gyulavari, Bianka Gurbi, Jozsef Muranyi, Peter Csermely, Miklos Csala, Tibor Vantus, Csaba Soti
Summary: Prostate cancer metastasis is a major cause of male mortality. Hsp90 promotes cancer cell migration by ensuring the conformational stability and function of PKD3, revealing a potential mechanism of Hsp90 in prostate cancer metastasis.
Article
Medicine, Research & Experimental
Huihui Fan, Jinze Li, Astrid M. Manuel, Zhongming Zhao
Summary: Prostate cancer is heterogeneous at both morphological and molecular levels, presenting challenges in early diagnosis and treatment. This study integrated single-cell sequencing to decode the epigenetic plasticity in prostate cancer cell lines upon enzalutamide treatment. Seven signature gene sets were identified, showing consistent trends of chromatin regulation and gene expression during early response and drug resistance. The findings provide potential biomarkers for predicting prognosis and suggest combinatory drug strategies to enhance treatment response or overcome resistance.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2023)
Article
Cell Biology
Jody Groenendyk, Konstantin Stoletov, Tautvydas Paskevicius, Wenjuan Li, Ning Dai, Myriam Pujol, Erin Busaan, Hoi Hei Ng, Aristeidis E. E. Boukouris, Bruno Saleme, Alois Haromy, Kaisa Cui, Miao Hu, Yanan Yan, Rui Zhang, Evangelos Michelakis, Xing-Zhen Chen, John D. D. Lewis, Jingfeng Tang, Luis B. B. Agellon, Marek Michalak
Summary: Elevation of SLC2A5 gene expression is associated with increased metastatic risk in cancer. Silencing SLC2A5 gene inhibits cancer cell proliferation, migration, and metastasis, and alters mitochondrial architecture and function. SLC2A5 is thus an important therapeutic target in cancer metastasis.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Cell Biology
Ying Fu, Yuan Sui, Yuming Zhao, Jianzhuo Jiang, Xueyuan Wang, Jiarui Cui, Xueqi Fu, Shu Xing, Zhizhuang Joe Zhao
Summary: PZR is a transmembrane glycoprotein encoded by the MPZL1 gene, and serves as a specific binding protein and substrate of tyrosine phosphatase SHP-2. Mutations in PZR are associated with developmental diseases and cancers. Bioinformatic analysis revealed that PZR is overexpressed in lung cancer and correlated with poor prognosis. Knockout and overexpression experiments demonstrated that PZR plays a crucial role in lung cancer development through regulating colony formation, migration, invasion, and tumor formation. The underlying mechanism involves activating tyrosine kinases FAK and c-Src, as well as maintaining intracellular ROS levels. These findings suggest that PZR may serve as a therapeutic target and biomarker for lung cancer.
Review
Oncology
Catherine S. Johnson, Leah M. Cook
Summary: One of the challenges in improving survival of prostate cancer is designing new therapies to target bone metastases. Although regulation of the bone environment has been well characterized, current bone-targeted therapies have limited impact on patient survival, highlighting the complexity of the tumor-bone environment. Chemokine signaling is an important factor in promoting prostate cancer progression in the bone. Understanding and targeting this signaling pathway may provide promising options for treating bone metastasis.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Seiji Omata, Keisuke Fukuda, Yurie Sakai, Kenoki Ohuchida, Yasuyuki Morita
Summary: Cancer incidence is increasing annually, and the invasion of cancer into the stroma significantly affects cancer metastasis. The purpose of this study is to clarify the effects of elastic modulus differences on cell migration behavior based on the same ECM fiber structure. We observe temporal changes in the morphology of cancer cells and the surrounding ECM to elucidate the relationship between changes in the mechanical properties of the ECM and the invasive behavior of cancer cells.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Oncology
Fan Chao, Zhenyu Song, Shiyu Wang, Zhe Ma, Zhiyuan Zhuo, Ting Meng, Guoxiong Xu, Gang Chen
Summary: This study investigates the role of circSOBP in prostate cancer metastasis and finds that circSOBP suppresses PCa cell migration and invasion by sponging miR-141-3p and regulating the MYPT1/p-MLC2 axis. Overexpression of circSOBP inhibits metastasis, while depletion increases migration and induces amoeboid migration. The results suggest that circSOBP could be a potential therapeutic target for preventing prostate cancer metastasis.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Galina Gritsina, Jindan Yu
Summary: Chemokines and their cognate receptors play a crucial role in tumor growth and dissemination, and ACKR3, also known as CXCR7, is a promising target for therapeutic intervention. Unlike CXCR4, CXCR7 activates beta-arrestin instead of G proteins upon binding to its ligand CXCL12, leading to rapid internalization and degradation of CXCL12 as a scavenger receptor. Recent evidence suggests that CXCR7 may have essential roles in cancer progression, independent of CXCR4 and its ligands. Constitutively active CXCR7 forms a protein complex with beta-arrestin, which assembles and activates various cytoplasmic kinases necessary for cell survival and tumor growth. This review discusses the current understanding of CXCR7 regulation and function, with a focus on prostate cancer.
Article
Medicine, Research & Experimental
Cho-Won Kim, Hong Kyu Lee, Min-Woo Nam, Gabsang Lee, Kyung-Chul Choi
Summary: This study found that KiSS1 overexpression increases the growth and migration of metastatic prostate cancer cells, as well as promoting tumor metastasis and angiogenesis. These findings highlight the critical role of KiSS1 in prostate cancer progression.
Article
Biotechnology & Applied Microbiology
Xun Zhang, Yujue Wang, Xue Wang, Bingyu Zou, Jie Mei, Xue Peng, Zhao Wu
Summary: Our study revealed that miR-10a-5p in CAF-derived EVs promotes angiogenesis and tumorigenesis of cervical squamous cell carcinoma cells by inhibiting TBX5 and activating the Hedgehog signaling pathway. These findings suggest a novel therapeutic strategy targeting miR-10a-5p against CSCC.
CANCER GENE THERAPY
(2021)
Article
Oncology
Giulia Spennati, Lisa F. Horowitz, David J. McGarry, Dominika A. Rudzka, Garett Armstrong, Michael F. Olson, Albert Folch, Huabing Yin
Summary: Metastasis is the primary cause of cancer patient mortality, and studying this process using organotypic liver and brain slices shows promise in closely replicating the tumour microenvironment for in vitro testing. Different invasion patterns and behaviors were observed in the breast cancer cells within the brain and liver slices, with variations in cell stiffness and adhesion forces influencing invasiveness. Inhibition of the Ras/MAPK/ERK pathway resulted in reduced invasiveness, highlighting the potential of organotypic tissue slices to better mimic in vivo conditions during cancer cell metastasis compared to traditional in vitro models.
EXPERIMENTAL CELL RESEARCH
(2021)
Article
Oncology
Marco Dicanio, Matteo Giaccherini, Alyssa Clay-Gilmour, Angelica Macauda, Juan Sainz, Mitchell J. Machiela, Malwina Rybicka-Ramos, Aaron D. Norman, Agata Tyczynska, Stephen J. Chanock, Torben Barington, Shaji K. Kumar, Parveen Bhatti, Wendy Cozen, Elizabeth E. Brown, Anna Suska, Eva K. Haastrup, Robert Z. Orlowski, Marek Dudzinski, Ramon Garcia-Sanz, Marcin Kruszewski, Joaquin Martinez-Lopez, Katia Beider, Elzbieta Iskierka-Jazdzewska, Matteo Pelosini, Sonja Berndt, Malgorzata Razny, Krzysztof Jamroziak, S. Vincent Rajkumar, Artur Jurczyszyn, Annette Juul Vangsted, Pilar Garrido Collado, Ulla Vogel, Jonathan N. Hofmann, Mario Petrini, Aleksandra Butrym, Susan L. Slager, Elad Ziv, Edyta Subocz, Graham G. Giles, Niels Frost Andersen, Grzegorz Mazur, Marzena Watek, Fabienne Lesueur, Michelle A. T. Hildebrandt, Daria Zawirska, Lene Hyldahl Ebbesen, Herlander Marques, Federica Gemignani, Charles Dumontet, Judit Varkonyi, Gabriele Buda, Arnon Nagler, Agnieszka Druzd-Sitek, Xifeng Wu, Katalin Kadar, Nicola J. Camp, Norbert Grzasko, Rosalie G. Waller, Celine Vachon, Federico Canzian, Daniele Campa
Summary: The aim of this study was to identify novel pleiotropic variants involved in multiple myeloma (MM) risk. Through analysis of 28,684 single nucleotide polymorphisms (SNPs), DNAJB4-rs34517439-A was found to be associated with an increased risk of developing MM.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
B. R. Shank, B. Primeaux, E. K. Yeung, S. B. Horowitz, I. Y. Lee, L. Roccograndi, L. Feng, G. P. Kaufman, H. C. Lee, E. E. Manasanch, K. K. Patel, R. Z. Orlowski, D. M. Weber, M. R. Becnel, S. K. Thomas
Summary: This retrospective analysis evaluated the safety and efficacy of hyperfractionated cyclophosphamide-dexamethasone (hyperCd) with or without carfilzomib and/or daratumumab as a potential treatment option for multiple myeloma. The study found that hyperCd-based therapy achieved rapid disease control, although hematologic toxicities were common but manageable.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Oncology
Meletios A. Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J. Bahlis, Saad Z. Usmani, Neil Rabin, Robert Z. Orlowski, Kenshi Suzuki, Torben Plesner, Sung-Soo Yoon, Dina Ben Yehuda, Paul G. Richardson, Hartmut Goldschmidt, Donna Reece, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Philippe Moreau
Summary: Based on the analysis of POLLUX, daratumumab in combination with lenalidomide and dexamethasone significantly prolonged progression-free survival in patients with relapsed or refractory multiple myeloma. The final analysis also showed that this combination therapy improved overall survival in these patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Hematology
Oren Pasvolsky, Rima M. Saliba, Adeel Masood, Ali H. Mohamedi, Mark R. Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Jeremy Ramdial, Yago Nieto, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Minghao Dang, Ruiping Wang, Hans C. Lee, Krina K. Patel, Melody R. Becnel, Guangchun Han, Sheeba K. Thomas, Dapeng Hao, Yanshuo Chu, Donna M. Weber, Pei Lin, Zuzana Lutter-Berka, David A. Berrios Nolasco, Mei Huang, Hima Bansal, Xingzhi Song, Jianhua Zhang, Andrew Futreal, Luz Yurany Moreno Rueda, David E. Symer, Michael R. Green, Cristhiam M. Rojas Hernandez, Michael Kroll, Vahid Afshar-Khargan, Libere J. Ndacayisaba, Peter Kuhn, Sattva S. Neelapu, Robert Z. Orlowski, Linghua Wang, Elisabet E. Manasanch
Summary: In this study, single-cell RNA and B cell receptor sequencing were used to analyze data from 52 patients with myeloma precursors. The study revealed early genomic drivers, distinct transcriptional features, and different clonal expansion patterns in hyperdiploid and non-hyperdiploid samples. Intra-patient heterogeneity was observed, along with unique patterns of evolution from myeloma precursor disease to myeloma. Additionally, distinctive characteristics of the microenvironment associated with specific genomic changes in myeloma cells were identified. These findings provide valuable insights into myeloma precursor disease progression and have implications for patient risk stratification, biomarker discovery, and potential clinical applications.
Editorial Material
Oncology
Thierry Facon, Shaji K. Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Aurore Perrot, Katja Weisel, Noopur Raje, Margaret Macro, Laurent Frenzel, Xavier Leleu, Jianping Wang, Rian Van Rampelbergh, Clarissa M. Uhlar, Jessica Vermeulen, Joana Duran, Fredrik Borgsten, Saad Z. Usmani
Article
Pathology
Fatima Zahra Jelloula, Andres E. Quesadaa, Richard K. Yanga, Shaoying Lia, Wei Wanga, Jie Xua, Guilin Tanga, C. Cameron Yina, Hong Fanga, Siba El Husseinb, Joseph Khourya, Roland L. Bassettc, Guillermo Garcia-Manerod, Elizabet E. Manasanche, Robert Z. Orlowskie, Muzaffar H. Qazilbashf, Keyur P. Patela, L. Jeffrey Medeirosa, Pei Lina
Summary: The development of therapy-related myeloid neoplasms (t-MN) is a rare complication in myeloma patients treated with novel therapies. Compared with a control group, these t-MNs were more likely to occur after multiple treatments and have a longer latency period in patients who received high-dose melphalan-based autologous stem cell transplantation (HDM-ASCT).
Article
Oncology
Oren Pasvolsky, Denai R. Milton, Mikael Rauf, Sassine Ghanem, Adeel Masood, Ali H. Mohamedi, Mark R. Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Guilin Tang, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Katy Rezvani, Richard Champlin, Elizabeth J. Shpall, Pei Lin, Muzaffar H. Qazilbash
Summary: A retrospective analysis showed that the presence and degree of clonal plasma cells (CPC) in the autograft were highly predictive of inferior progression free survival (PFS) and overall survival (OS) in multiple myeloma (MM) patients undergoing autologous hematopoietic stem cell transplantation (autoHCT).
BLOOD CANCER JOURNAL
(2023)
Review
Chemistry, Medicinal
Upasana Ray, Robert Z. Orlowski
Summary: Multiple myeloma is often treated with monoclonal antibodies targeting specific markers or as antibody-drug conjugates. There are several approved antibodies for treatment, such as daratumumab and isatuximab targeting CD38, elotuzumab targeting Signaling lymphocytic activation molecule family member 7, and teclistamab targeting BCMA. Belantamab mafodotin is an ADC that gained attention but faced withdrawal due to negative Phase III results. Despite this setback, there are other ADCs in development targeting BCMA or other plasma cell surface markers. Overall, ADCs have potential as part of chemotherapy against myeloma.
Article
Hematology
Oren Pasvolsky, Denai R. Milton, Adeel Masood, Sophiya S. Sami, Mark R. Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Arsalan Saeed, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash
Summary: The optimal duration of Len maintenance for MM patients after autoHCT is uncertain. A retrospective analysis was conducted on MM patients who underwent upfront autoHCT followed by single-agent Len maintenance between 2005 and 2021. The results showed that longer maintenance duration, even beyond 5 years, was associated with improved survival. However, longer maintenance duration was also linked to a higher risk of developing a second primary malignancy (SPM).
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Oren Pasvolsky, Curtis Marcoux, Denai R. Milton, Mark R. Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Priti Tewari, Lindsay Crawford-Suber, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash
Summary: This study analyzed the data of 117 young adults with multiple myeloma (MM) undergoing autologous transplantation and found that auto-HCT had a favorable outcome for them. Furthermore, the survival of younger MM patients improved with the availability of novel anti-myeloma drugs in recent years. Depth of response following transplant was a key predictor of survival.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Medicine, General & Internal
P. G. Richardson, S. Trudel, R. Popat, M- Mateos, A. J. Vangsted, K. Ramasamy, J. Martinez-Lopez, H. Quach, R. Z. Orlowski, M. Arnao, S. Lonial, C. Karanes, C. Pawlyn, K. Kim, A. Oriol, J. G. Berdeja, P. Rodriguez Otero, I Casas-Aviles, A. Spirli, J. Poon, S. Li, J. Gong, L. Wong, M. Lamba, D. W. Pierce, M. Amatangelo, T. Peluso, P. Maciag, J. Katz, Michael Pourdehnad, Nizar J. Bahlis
Summary: In this study, patients with relapsed and refractory multiple myeloma received oral mezigdomide in combination with dexamethasone. The combination therapy showed promising efficacy in heavily pretreated patients with multiple myeloma, with treatment-related adverse events consisting mainly of myelotoxic effects.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Sonia M. Setayesh, Libere J. Ndacayisaba, Kate E. Rappard, Valerie Hennes, Luz Yurany Moreno Rueda, Guilin Tang, Pei Lin, Robert Z. Orlowski, David E. Symer, Elisabet E. Manasanch, Stephanie N. Shishido, Peter Kuhn
Summary: This study demonstrates the applicability of single-cell high-definition liquid biopsy assay and imaging mass cytometry to characterize the proteomic profile of multiple myeloma. It identifies potential therapeutic targets and reveals the differential expression of clinical markers across different stages of the disease.
NPJ PRECISION ONCOLOGY
(2023)
Article
Hematology
Saurabh Chhabra, Natalie Callander, Nicole L. Watts, Luciano J. Costa, Bicky Thapa, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Larry D. Anderson, Susan Bal, Binod Dhakal, Nitya Nathwani, Nina Shah, Eva Medvedova, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Timothy Schmidt, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Bhagirathbhai Dholaria, R. Frank Cornell, James H. Jerkins, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Saad Z. Usmani, Paul G. Richardson, Peter M. Voorhees
Summary: For eligible patients with newly diagnosed multiple myeloma (NDMM), standard of care includes induction therapy followed by autologous stem cell transplantation (ASCT). Daratumumab as monotherapy and in combination treatment is approved across multiple lines of therapy for multiple myeloma (MM), and lenalidomide is an effective and commonly used agent for induction and maintenance therapy in MM. However, there is concern that lenalidomide and daratumumab given as induction therapy might impair mobilization of stem cells for ASCT.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Ethan P. Damron, Muzaffar H. Qazilbash, Penny Q. Fang, Susan Y. Wu, Bouthaina S. Dabaja, Gabriela Rondon, Chitra Hosing, Richard E. Champlin, Qaiser Bashir, Elizabeth J. Shpall, Mark K. Knafl, Hans C. Lee, Elisabet E. Manasanch, Krina Patel, Sheeba K. Thomas, Robert Z. Orlowski, Donna M. Weber, Chelsea C. Pinnix, Jillian R. Gunther
Summary: The primary treatment of multiple myeloma (MM) often includes systemic induction therapy (SIT) and autologous stem cell transplantation (ASCT). However, radiation therapy (RT) is sometimes avoided due to concerns about its effect on peripheral blood progenitor cell (PBPC) collection for ASCT. This study retrospectively examined the possible impact of RT on PBPC collection in MM patients. The results showed that RT prior to ASCT did not impair the successful collection of PBPCs.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Biochemistry & Molecular Biology
Kun He, Mengyi Xie, Weifeng Hong, Yonghe Li, Yaolin Yin, Xiaojin Gao, Yi He, Yu Chen, Chuan You, Jingdong Li
Summary: Centromere protein L (CENPL) is overexpressed in hepatocellular carcinoma (HCC) and is associated with poor patient prognosis. Upregulation of CENPL promotes tumor proliferation and glycolysis in HCC cells by activating the MEK1/2-ERK1/2 signaling pathway.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
(2024)
Article
Biochemistry & Molecular Biology
Yingzi Wang, Haozhong Huang, Huimin Weng, Chunsen Jia, Bin Liao, Yang Long, Fengxu Yu, Yongmei Nie
Summary: Talin protein plays a crucial role in transmitting mechanical forces by connecting the extracellular matrix to the cytoskeleton. It converts mechanical signals into biochemical signals and serves as diagnostic, therapeutic, and prognostic indicators in diseases.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
(2024)
Review
Biochemistry & Molecular Biology
Hema Saranya Ilamathi, Marc Germain
Summary: Mitochondria are the central metabolic hubs in cells, relying on proteins encoded by nuclear DNA and mitochondrial DNA (mtDNA) for their function. The maintenance and distribution of mtDNA are crucial for proper mitochondrial function and are associated with mitochondrial diseases. mtDNA is organized into nucleoids that dynamically move and interact with each other. The replication and distribution of mtDNA nucleoids are regulated by the complex interplay of mitochondrial dynamics, ER-mitochondria contact sites, and cytoskeletal networks.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
(2024)
Article
Biochemistry & Molecular Biology
K. K. Sruthi, Sirisha Natani, Ramesh Ummanni
Summary: The overexpression of TPD52 is associated with the emergence of neuroendocrine prostate cancer (NEPC). TPD52 activates the NF-kappa B - STAT3 axis to induce neuroendocrine differentiation (NED) of prostate cancer cells. Therapeutic targeting of TPD52 is important for the treatment of prostate cancer.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
(2024)
Article
Biochemistry & Molecular Biology
Cui Li, Feifan Xiang, Yuqi Gong, Yi Fu, Ge Chen, Zhi Wang, Zhong Li, Daiqing Wei
Summary: Our study demonstrates the significant role of tumor-derived microparticles (T-MPs) in osteosarcoma metastasis and immune response. T-MPs promote macrophage polarization and stimulate migration and chemoresistance of osteosarcoma cells, thereby affecting the progression of osteosarcoma.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
(2024)
